The Alexandria Real Estate Equities-backed regenerative medicine developer floated at the bottom of its range while cutting the number of shares.
Frequency Therapeutics, a US-based degenerative disease drug developer backed by life sciences real estate investment trust Alexandria Real Estate Equities, went public today in an $84m initial public offering.
The company floated at the foot of the $14 to $16 range it set last month, while reducing the number of shares in the IPO from 6.7 million to 6 million. It is valued at approximately $424m in the offering.
Frequency is developing regenerative medicines designed to use progenitor cell…
